Published in Cancer Weekly, March 1st, 2005
Osiris believes FDA's decision makes the company the first to receive Fast Track designation for a preformulated stem cell drug.
Prochymal, now entering phase II clinical trials, is a formulation of a specific type of adult stem cell that has the ability to modulate the immune system in a way that may benefit patients suffering from a variety of immunological problems.
This new approach may...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.